Top Medical Searches

FDA approves Marathon Pharmaceuticals DMD drug

A view shows the U.S. Food and Drug Administration headquarters in Silver Spring(Reuters) – The U.S. Food and Drug Administration on Thursday approved Marathon Pharmaceuticals' Duchenne muscular dystrophy (DMD) drug, Emflaza, to treat patients aged 5 years and above. DMD is a rare genetic disorder that causes progressive muscle deterioration and weakness and had only one approved treatment in the United States before Emflaza's approval. The FDA in September approved Sarepta Therapeutics Inc's DMD treatment even though an outside panel of experts and the agency's own reviewers questioned the drug's efficacy. …

Read More..

Be Sociable, Share!
February 9th, 2017 Posted in Drug
Copyright 2008 © Drugs and Diseases. Developed by Axilosoft
Home | About Us | Privacy Policy | Contact Us